RxMP Therapeutics
RxMP Therapeutics, INC is dedicated to addressing the critical need for effective hemostatic agents to prevent and treat excessive bleeding associated with trauma, surgery, or bleeding disorders. The company leverages exclusive technology to manufacture red cell-derived microparticles (RMPs), which are designed to normalize and accelerate the body's natural clotting process without triggering unwanted clotting. Their mission is to provide innovative, scalable, and stable solutions that can be used systemically to prevent or arrest bleeding, offering a significant advancement over traditional transfusion therapies.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Composition comprising red cell-derived microparticles and method of treating excessive bleeding
US-11241457-B2
View Details
Composition comprising red cell-derived microparticles and method of treating excessive bleeding
US-11241457-B2
View DetailsProducts
Red blood cell-derived microparticle hemostatic agent
A biologic hemostatic agent composed of microparticles derived from donor red blood cells, manufactured via a scalable physical process and freeze-dried for long-term storage; intended for systemic administration to prevent or stop excessive bleeding in therapeutic or prophylactic settings.
Red blood cell-derived microparticle hemostatic agent
A biologic hemostatic agent composed of microparticles derived from donor red blood cells, manufactured via a scalable physical process and freeze-dried for long-term storage; intended for systemic administration to prevent or stop excessive bleeding in therapeutic or prophylactic settings.
Expertise Areas
- Hemostatic therapeutic development
- Blood-derived biologics manufacturing
- Lyophilized biologic formulation and storage
- Systemic parenteral hemostatic therapy
Key Technologies
- Red blood cell-derived microparticles
- Lyophilization (freeze-drying)
- Scalable physical manufacturing processes for blood products
- Systemic parenteral formulation